Key Details
Price
$49.00Last Dividend
$2.04Annual ROE
7.18%Beta
0.06Events Calendar
Next earnings date:
Jan 31, 2025Recent quarterly earnings:
Oct 25, 2024Recent annual earnings:
Feb 01, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
May 09, 2024Next split:
N/ARecent split:
Sept 30, 2013Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
The facility, known as Modulus, can switch between making different vaccines or treatments in a matter of days. It will contribute about 200 skilled jobs to Singapore, and will be fully operational by mid-2026.
French drugmaker Sanofi plans to change its policy on how it gives discounts to certain U.S. hospitals that serve low-income and uninsured patients, the Wall Street Journal reported on Friday.
The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for chronic spontaneous urticaria on April 18, 2025.
Rob Koremans, CEO of Italian pharmaceutical company Recordati, weighs in on the company's purchase of Sanofi's rare immune disorder drug, Enjaymo.
Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma Recommendation based on IMROZ phase 3 study demonstrating Sarclisa in combination with VRd significantly improved progression-free survival, compared to standard-of-care VRd alone If approved, Sarclisa would be the first anti-CD38 therapy in the EU available for use in combination with VRd for adult patients with transplant-ineligible NDMM Paris, November 14, 2024. The European Medicines Agency (EMA)'s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for the treatment of adult patients with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplant (ASCT).
Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse drug portfolio and a robust pipeline of future drugs to market, this big pharma brand will play a major role in treatments in the next decades to come. The stock currently offers a 4% dividend yield, while trading below its moving average and with a mixed valuation picture vs key peers.
BURLINGAME, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Accumulus Synergy, Inc. (“Accumulus”), is revolutionizing the scalability of reliance pathways, enabling a recent submission from Sanofi to multiple national regulatory authorities (NRAs) around the globe. As industry leaders are set to leverage the Accumulus platform for upcoming projects, its ability to handle concurrent submissions across multiple jurisdictions is proving to be a game-changer.
Jack Hidary, CEO of SandboxAQ, says the firm's partnership with Sanofi aims to drive biomarker discovery in clinical development.
TORINO, Italy--(BUSINESS WIRE)--Resalis Therapeutics announced today a strategic equity investment from Sanofi. The company intends to use the proceeds to accelerate the development of its lead investigational candidate, RES-010, through a Phase 2 proof-of-concept clinical trial. RES-010 represents a first-in-class antisense oligonucleotide targeting miR-22, a non-coding RNA that plays a pivotal role in the molecular pathways underlying obesity. This innovative approach positions Resalis to pot.
FAQ
- What is the primary business of Sanofi?
- What is the ticker symbol for Sanofi?
- Does Sanofi pay dividends?
- What sector is Sanofi in?
- What industry is Sanofi in?
- What country is Sanofi based in?
- When did Sanofi go public?
- Is Sanofi in the S&P 500?
- Is Sanofi in the NASDAQ 100?
- Is Sanofi in the Dow Jones?
- When was Sanofi's last earnings report?
- When does Sanofi report earnings?